Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in US Hospitals during 2014 to 2018

被引：28

作者：

Carvalhaes, Cecilia G. ^{[1
]}

Shortridge, Dee ^{[1
]}

Sader, Helio S. ^{[1
]}

Castanheira, Mariana ^{[1
]}

机构：

[1] JMI Labs, North Liberty, IA 52317 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2020年 / 64卷 / 03期

关键词：

CPE; CRE; Enterobacterales; Enterobacteriaceae; HAP; Pseudomonas aeruginosa; VAP; carbapenemase; hospital-acquired pneumonia; ventilator-acquired pneumonia; VENTILATOR-ASSOCIATED PNEUMONIA; ENTEROBACTERIACEAE; MORTALITY; RPX7009; SAFETY;

D O I：

10.1128/AAC.02177-19

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Meropenem-vaborbactam is approved to treat hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), in Europe. Meropenem-vaborbactam activity was evaluated against 3,193 Pseudomonas aeruginosa and 4,790 Enterobacterales isolates causing pneumonia, including VAP, in hospitalized patients in the United States. Susceptibility testing was performed by using the broth microdilution method, and all carbapenem-resistant isolates were submitted for whole-genome sequencing. Meropenem-vaborbactam exhibited almost complete activity against Enterobacterales (>99.9% susceptible), including carbapenem-resistant Enterobacterales (CRE), and was also very active against P. aeruginosa isolates (89.5% susceptible).

引用

页数：7

共 40 条

[1]

[Anonymous], 2018, TYGACIL PRODUCT INFO

[2]

[Anonymous], 2019, Breakpoint tables for interpretation of MICs and zone diameters

[3]

[Anonymous], 2018, Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically

[4]

Approved Standard-Ninth Edition. CLSI document M07 Ed11

[5] Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management [J].